Main Story
-
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage
NANJING, China, Aug. 24, 2026 (GLOBE NEWSWIRE) — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that Opamtistomig (LBL-024), the Company’s proprietary PD-L1/4-1BB bispecific antibody, as a first-line treatment for locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), has completed its safety run‑in assessment and advanced to…
Products
-
AccuSure AS9 Fully Automatic Digital Blood Pressure Monitor With Large Display
Original price was: ₹1,733.00.₹998.00Current price is: ₹998.00. -
AGEasy Max Group Fully Automatic One Touch Digital Blood Pressure Monitoring Device
Original price was: ₹1,405.00.₹949.00Current price is: ₹949.00. -
Automatic Digital Blood Pressure Monitor for Upper Arm, Large LCD Display
Original price was: ₹2,399.00.₹448.00Current price is: ₹448.00. -
Beurer German Engineering P0 13 Kid’s Pulse Oximeter I Fingertip Home Pulse Oximeter
Original price was: ₹2,745.00.₹1,538.00Current price is: ₹1,538.00. -
BPL Medical Technologies Bluetooth Enabled Arm Type Blood Pressure Monitor
Original price was: ₹6,563.00.₹5,199.00Current price is: ₹5,199.00.
Automobile
Tech
Entertainment
-
Timezone and Play 'N' Learn Unveil the Ultimate Fun Destination for All Ages at Pacific Mall, Delhi
The refreshed destination brings together immersive play, new age interactive experiences, celebrations, dining and family-friendly entertainment for all ages under one roof New Delhi, Delhi, India Timezone and Play ‘N’ Learn have relaunched their entertainment spaces together at Pacific Mall, Delhi, unveiling a refreshed line-up of experiences for families, friends and guests across age groups.…
Health
-
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage
NANJING, China, Aug. 24, 2026 (GLOBE NEWSWIRE) — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that Opamtistomig (LBL-024), the Company’s proprietary PD-L1/4-1BB bispecific antibody, as a first-line treatment for locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), has completed its safety run‑in assessment and advanced to…
-
ICP DAS-BMP Brings Advanced Medical TPU Portfolio to Medical Manufacturing Asia 2026
HSINCHU, Aug. 25, 2026 /PRNewswire/ — ICP DAS-BMP (Biomedical Polymers), a Taiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), will exhibit at Medical Manufacturing Asia 2026, taking place September 9–11 at the Marina Bay Sands Expo & Convention Centre in Singapore (Booth 2U20). Exhibiting together with its manufacturing partner, Towards Buddha Co., Ltd., the…
-
TME Pharma provides update on its activities
TME Pharma enters final evaluation phase with two potential partners for licensing lead asset NOX-A12 to support Phase 2 glioblastoma development Source: TME Pharma provides update on its activities
-
Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
TAIPEI, Aug. 24, 2026 /PRNewswire/ — Anbogen Therapeutics Inc. (TPEx: 7784) (“Anbogen” or the “Company”), a clinical-stage precision oncology company, today announced that it has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, to evaluate ABT-301 (Imofinostat), the Company’s selective…
-
Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
Orum receives FDA clearance for ORM-1153, advancing its novel CD123-GSPT1 degrader-antibody conjugate toward Phase 1 in hematologic malignancies. Source: Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
-
ZEISS CLINIC 360 receives FDA 510k clearance, amplifying patient care through simplified clinical insights
The ZEISS CLINIC 360 all-in-one browser-based software solution aggregates clinical data at scale and powers advanced analytics for streamlined ophthalmic workflows, providing clinicians with more time for personalizing patient care. JENA, Germany, Aug. 19, 2026 /PRNewswire/ — ZEISS Medical Technology, one of the world’s leading medical technology companies, today announced the 510k clearance from the U.S.…
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
